| Patient gender, M/F | 69/41 |
| Median age at diagnosis, years (range) | 1.4 (0.1-6.4) |
| Median age at UCBT, years (range) | 2.2 (0.5-7.4) |
| Median time interval between diagnosis and UCBT, months (range) | 5.6 (1.1-58.1) |
| Karyotype analysis | |
| Normal (%) | 44 (40) |
| Abnormal (%) | 30 (27) |
| Not done (%) | 4 (4) |
| Missing (%) | 32 (29) |
| Cytogenetic abnormalities | |
| Monosomy 7 (%) | 19 (63.3) |
| Monosomy 7 + other (%) | 1 (3.3) |
| Trisomy 8 (%) | 1 (3.3) |
| Other (%) | 9 (30) |
| Median percentage of HbF at diagnosis (range)* | 13 (1-70) |
| Median WBC at diagnosis (range)† | 35 (4.2-220.0) |
| Median monocyte count at diagnosis × 109/L (range)‡ | 7.0 (1.1-74.8) |
| Median platelet count at diagnosis × 109/L (range)§ | 42.5 (5-302) |
| Median WBC at UCBT × 109/L (range)∥ | 11.35 (0.2-90.0) |
| Median percentage of BM blasts at UCBT (range)¶ | 6 (0-20) |
| Splenectomy before UCBT | |
| Yes (%) | 28 (26) |
| No (%) | 74 (67) |
| Missing (%) | 8 (7) |
| Pre-HSCT treatment | |
| None or low dose | 68 (62) |
| AML like | 34 (31) |
| Missing (%) | 8 (7) |
| Patient HCMV serology | |
| Negative (%) | 49 (44) |
| Positive (%) | 61 (56) |
| ABO matching in the recipient/donor pair | |
| Matched (%) | 48 (43) |
| Major incompatibility (%) | 33 (30) |
| Minor incompatibility (%) | 26 (24) |
| Missing (%) | 3 (3) |
| Use of serotherapy before transplantation | |
| Yes (%) | 94 (85) |
| No (%) | 15 (14) |
| Missing (%) | 1 (1) |
| Median number of cells infused × 107/kg patient body weight (range) | 7.1 (1.7-27.6) |
| Patient gender, M/F | 69/41 |
| Median age at diagnosis, years (range) | 1.4 (0.1-6.4) |
| Median age at UCBT, years (range) | 2.2 (0.5-7.4) |
| Median time interval between diagnosis and UCBT, months (range) | 5.6 (1.1-58.1) |
| Karyotype analysis | |
| Normal (%) | 44 (40) |
| Abnormal (%) | 30 (27) |
| Not done (%) | 4 (4) |
| Missing (%) | 32 (29) |
| Cytogenetic abnormalities | |
| Monosomy 7 (%) | 19 (63.3) |
| Monosomy 7 + other (%) | 1 (3.3) |
| Trisomy 8 (%) | 1 (3.3) |
| Other (%) | 9 (30) |
| Median percentage of HbF at diagnosis (range)* | 13 (1-70) |
| Median WBC at diagnosis (range)† | 35 (4.2-220.0) |
| Median monocyte count at diagnosis × 109/L (range)‡ | 7.0 (1.1-74.8) |
| Median platelet count at diagnosis × 109/L (range)§ | 42.5 (5-302) |
| Median WBC at UCBT × 109/L (range)∥ | 11.35 (0.2-90.0) |
| Median percentage of BM blasts at UCBT (range)¶ | 6 (0-20) |
| Splenectomy before UCBT | |
| Yes (%) | 28 (26) |
| No (%) | 74 (67) |
| Missing (%) | 8 (7) |
| Pre-HSCT treatment | |
| None or low dose | 68 (62) |
| AML like | 34 (31) |
| Missing (%) | 8 (7) |
| Patient HCMV serology | |
| Negative (%) | 49 (44) |
| Positive (%) | 61 (56) |
| ABO matching in the recipient/donor pair | |
| Matched (%) | 48 (43) |
| Major incompatibility (%) | 33 (30) |
| Minor incompatibility (%) | 26 (24) |
| Missing (%) | 3 (3) |
| Use of serotherapy before transplantation | |
| Yes (%) | 94 (85) |
| No (%) | 15 (14) |
| Missing (%) | 1 (1) |
| Median number of cells infused × 107/kg patient body weight (range) | 7.1 (1.7-27.6) |